Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTBNASDAQ:MOLNNASDAQ:NLTXNASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$0.81-1.0%$0.74$0.51▼$2.07$45.06M-0.356,098 shs21,817 shsMOLNMolecular Partners$3.58-5.7%$3.93$3.36▼$12.70$144.34M1.1520,918 shs8,185 shsNLTXNeoleukin Therapeutics$17.75+4.4%$13.92$2.03▼$14.36$166.81M1.1150,104 shs210,536 shsRAPTRAPT Therapeutics$0.99+5.3%$0.93$0.71▼$4.60$130.70M-0.041.28 million shs639,537 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+4.80%+8.52%-0.70%-4.95%-54.23%MOLNMolecular Partners-3.05%-6.64%-7.23%-19.12%+5.14%NLTXNeoleukin Therapeutics0.00%-1.56%+0.24%+4.94%-54.76%RAPTRAPT Therapeutics+5.00%-23.73%-2.97%-14.72%-76.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma2.9499 of 5 stars3.53.00.00.02.92.50.6MOLNMolecular Partners2.5451 of 5 stars3.84.00.00.02.20.00.6NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARAPTRAPT Therapeutics4.0043 of 5 stars3.21.00.04.23.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.00Buy$8.00886.44% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00235.66% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ARAPTRAPT Therapeutics 2.33Hold$3.00203.64% UpsideCurrent Analyst Ratings BreakdownLatest CNTB, MOLN, RAPT, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.005/22/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$6.003/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/10/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$26.03M1.73N/AN/A$1.83 per share0.44MOLNMolecular Partners$2.23M64.67N/AN/A$5.41 per share0.66NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ARAPTRAPT Therapeutics$1.53M85.43N/AN/A$4.27 per share0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/AMOLNMolecular Partners-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%N/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ARAPTRAPT Therapeutics-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%8/14/2025 (Estimated)Latest CNTB, MOLN, RAPT, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/8/2025Q1 2025RAPTRAPT Therapeutics-$0.31-$0.08+$0.23-$0.08N/AN/A3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/A3/6/2025Q4 2024RAPTRAPT Therapeutics-$0.45-$1.14-$0.69-$1.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect BiopharmaN/A12.04N/AMOLNMolecular PartnersN/A14.3314.33NLTXNeoleukin TherapeuticsN/A15.3315.33RAPTRAPT TherapeuticsN/A9.909.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%MOLNMolecular Partners26.55%NLTXNeoleukin Therapeutics52.37%RAPTRAPT Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%MOLNMolecular Partners5.93%NLTXNeoleukin Therapeutics1.58%RAPTRAPT Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.56 million42.77 millionOptionableMOLNMolecular Partners18040.38 million37.97 millionNot OptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataRAPTRAPT Therapeutics80132.29 million32.65 millionOptionableCNTB, MOLN, RAPT, and NLTX HeadlinesRecent News About These CompaniesRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from BrokeragesJune 3 at 1:33 AM | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%June 2 at 3:39 PM | marketbeat.comWhat is HC Wainwright's Forecast for RAPT Q2 Earnings?May 27, 2025 | marketbeat.com12 Health Care Stocks Moving In Friday's Intraday SessionMay 25, 2025 | benzinga.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to Strong-Buy at HC WainwrightMay 25, 2025 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street ZenMay 24, 2025 | marketbeat.comUBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock PriceMay 24, 2025 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC WainwrightMay 24, 2025 | marketbeat.com11,764,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by RTW Investments LPMay 18, 2025 | marketbeat.comRapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should KnowMay 16, 2025 | zacks.com13,135,260 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by AnalystsMay 11, 2025 | marketbeat.comDeep Track Capital LP Invests $9.50 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comColumn Group LLC Lowers Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comRAPT Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comWhy RAPT Therapeutics, Inc.’s (RAPT) Stock Is Down 5.55%May 8, 2025 | aaii.comBVF Inc. IL Acquires New Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 6, 2025 | marketbeat.comRAPT Therapeutics (RAPT) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comIs RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?April 18, 2025 | finance.yahoo.comRapt Therapeutics appoints Jessica Savage as VP, clinical developmentApril 17, 2025 | markets.businessinsider.comRAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical DevelopmentApril 15, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTB, MOLN, RAPT, and NLTX Company DescriptionsConnect Biopharma NASDAQ:CNTB$0.81 -0.01 (-1.01%) Closing price 03:59 PM EasternExtended Trading$0.82 +0.00 (+0.49%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Molecular Partners NASDAQ:MOLN$3.58 -0.22 (-5.67%) Closing price 03:36 PM EasternExtended Trading$3.58 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Neoleukin Therapeutics NASDAQ:NLTX$17.75 +0.74 (+4.35%) As of 06/2/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.RAPT Therapeutics NASDAQ:RAPT$0.99 +0.05 (+5.32%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.00 (+0.10%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
